{
    "clinical_study": {
        "@rank": "13325", 
        "acronym": "IRENE", 
        "arm_group": {
            "arm_group_label": "renal tumor <4cm, suspected RCC", 
            "arm_group_type": "Experimental", 
            "description": "Intervention/ Time point: Irreversible Electroporation at day 0 of each patient."
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is the evaluation of the ablation efficiency of the percutaneous\n      irreversible electroporation (IRE) as primary ablation therapy of locally confined renal\n      cell carcinoma (\u22644cm, see inclusion and exclusion criteria).\n\n      The ablation success will be proofed by magnet resonance imaging (MRI) and histologically\n      after partial kidney resection or nephrectomy 4 weeks after IRE. Hypotheses: Kidney tumors\n      \u22644cm can be ablated completely by percutaneous IRE. Surrounded structures and renal tissue\n      can be preserved."
        }, 
        "brief_title": "IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Kidney Tumor", 
            "Renal Cell Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Health Condition or Problem studied:\n\n        1. International Statistical Classification of Diseases and Related Health Problems, Tenth\n           Revision (ICD10):   C64 -  Malignant neoplasm of kidney, except renal pelvis\n\n        2. ICD10:   D41.0 -  Neoplasm of uncertain or unknown behaviour: Kidney\n\n      Interventions/Observational Groups Arm 1:\n\n        1. Initial diagnostical examination of the renal mass.\n\n        2. If any extended diagnostical examination for treatment planning.\n\n        3. Day -29 to -1: Recruitment.\n\n        4. Day -1: MRI of the kidney, Karnofsky, physical examination, blood chemistry,\n           urosonography, if any renal scintigraphy, life quality assessment.\n\n        5. Day 0: Percutaneous diagnostical biopsy with histopathological investigation and\n           therapeutically, CT- and/or ultrasound-guided, ECG-synchronized irreversible\n           electroporation (IRE) of the kidney tumor in endotracheal anaesthesia und muscle\n           relaxation. Use of 1-6 IRE probes with 90-100 pulses of 1500-3000 volts und 20-50\n           amperes each.\n\n        6. Day 1-7: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical\n           examination, blood chemistry, urosonography, life quality assessment.\n\n        7. Day 27: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical\n           examination, blood chemistry, urosonography, if any renal scintigraphy, life quality\n           assessment.\n\n        8. Day 28: Open surgery partial kidney resection or tumor nephrectomy of the IRE treated\n           kidney resp. kidney tumor region with histopathological investigation.\n\n        9. Day 29-37: Postoperative follow-up: physical examination, blood chemistry,\n           urosonography, life quality assessment.\n\n       10. Day 112: Study-Follow-up: MRI of the kidneys, Karnofsky, physical examination, blood\n           chemistry, urosonography, if any renal scintigraphy, life quality assessment.\n           Termination of the study.\n\n       11. Study closed, Individual follow-up due to the European Association of Urology\n           guideline.\n\n      Recruitment:\n\n        -  (Anticipated or Actual) Date of First Enrollment:  2013/10/14\n\n        -  Planned/Actual:  Opened\n\n        -  Target Sample Size:  20\n\n        -  Monocentric/Multicentric trial:  Monocentric trial\n\n        -  National/International:  National"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  one or more localized, resectable kidney tumors (\u22644 cm) suspicious of malignancy or\n             histology -proven renal cell cancer (RCC)\n\n          -  patients desire for therapy and surgical therapy\n\n          -  Karnofsky-index >70%\n\n          -  Age \u2265 18 years\n\n          -  life expectancy \u2265 12 month\n\n          -  compliance of the patient taking part in a study\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  violation against one or more inclusion criteria\n\n          -  cardial pacemaker or other electrical implants\n\n          -  QT-interval >550 ms or cardiac arrhythmias or condition after myocardial infarction,\n             that make an ECG-synchronisation unfeasible\n\n          -  cardial ejection fraction < 30%\n\n          -  known epilepsy\n\n          -  second malignancy (except basal-cell carcinoma and cervical carcinoma in situ)\n\n          -  immunosuppression or HIV-positive patients\n\n          -  active infection or severe health interference, that make taking part in a study\n             unfeasible\n\n          -  pregnancy, lactation period, no contraception\n\n          -  metastatic disease\n\n          -  palliative status\n\n          -  running or executed RCC therapy\n\n          -  taking part in another clinical study for RCC\n\n          -  inoperable\n\n          -  rejection of interventional or surgical therapy by the patient\n\n          -  circulatory instability\n\n          -  general contraindications for anesthesia, endotracheal anesthesia and muscle\n             relaxation\n\n          -  psychiatric disorders that make taking part in a study or giving informed consent\n             unfeasible\n\n          -  haemorrhage, impossible intermission of taking blood thinner, untreatable\n             thrombophilia\n\n          -  thromboplastin time \u226450 %, thrombocytes \u226450 Gpt/L; partial thromboplastin time >50\n\n          -  MRI incompatibility\n\n          -  metal implants <1 cm closed to the kidney / kidney tumor\n\n          -  contraindication for biopsy and punction of the renal tumor under CT-guidance\n\n          -  untreated urinary retention\n\n          -  renal pelvis tumor, suspected transitional cell cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967407", 
            "org_study_id": "DE-UKMD-URO-001", 
            "secondary_id": [
                "DRKS00004266", 
                "U1111-1140-0415", 
                "DRKS00004266", 
                "EUDAMED-No.: CIV-12-04-006021", 
                "00020520"
            ]
        }, 
        "intervention": {
            "arm_group_label": "renal tumor <4cm, suspected RCC", 
            "description": "Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.", 
            "intervention_name": "Irreversible Electroporation (IRE)", 
            "intervention_type": "Procedure", 
            "other_name": "NanoKnife (Tissue Ablation) System, AngioDynamics Inc."
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "kidney tumor", 
            "renal cell cancer", 
            "RCC", 
            "irreversible electroporation", 
            "IRE", 
            "partial kidney resection", 
            "percutaneous", 
            "ablation", 
            "IRENE"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "link": [
            {
                "description": "Department of Urology, University Magdeburg", 
                "url": "http://urologie.med.uni-magdeburg.de/urologie.html"
            }, 
            {
                "description": "German Clinical Trials Register (DRKS)", 
                "url": "https://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=start&messageDE=Home&messageEN=Home"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "state": "Sachsen-Anhalt", 
                        "zip": "39120"
                    }, 
                    "name": "Department of Urology University Hospital Otto-von-Guericke-University Magdeburg"
                }, 
                "investigator": [
                    {
                        "last_name": "Markus Porsch, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Andreas Janitzky, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Daniel Baumunk, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Daniel Schindele, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Simon Blaschke", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "state": "Sachsen-Anhalt", 
                        "zip": "39120"
                    }, 
                    "name": "Department of Radiology University Hospital Otto-von-Guericke-University Magdeburg"
                }, 
                "investigator": [
                    {
                        "last_name": "Jens Ricke, Prof.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Frank Fischbach, Prof.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Maciej Pech, Prof.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Julian J\u00fcrgens", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "state": "Sachsen-Anhalt", 
                        "zip": "39120"
                    }, 
                    "name": "Department of Pathology University Hospital Otto-von-Guericke-University Magdeburg"
                }, 
                "investigator": [
                    {
                        "last_name": "Sandra B\u00f6ttcher, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Albert Roessner, Prof.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Monocentric, Clinical Phase-I/II Study of the Effectiveness of the Percutaneous Irreversible Electroporation (IRE) of Locally Confined Kidney Tumors (Renal Cell Carcinomas).", 
        "overall_contact": {
            "email": "antje.wiede@med.ovgu.de", 
            "last_name": "Antje Wiede, Dr.", 
            "phone": "+493916721841"
        }, 
        "overall_contact_backup": {
            "email": "johann.wendler@med.ovgu.de", 
            "last_name": "Johann J. Wendler, Dr. med.", 
            "phone": "+493916715036"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Urology, University Magdeburg, Germany.", 
                "last_name": "Uwe- B. Liehr, Dr. med.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Urology, University Magdeburg, Germany", 
                "last_name": "Martin Schostak, Prof. Dr.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Department of Urology, University Magdeburg, Germany", 
                "last_name": "Johann J. Wendler, Dr. med.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: German Institute of Medical Documentation and Information"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "onco-therapeutic effectiveness, measured against persistent active tumor / cancer cells by histopathological and magnet resonance imaging analysis", 
            "measure": "analysis of ablation effectiveness of non-metastatic renal tumors <4cm 28 days by after irreversible electroporation (NanoKnife, AngioDynamics Inc.) by histopathological examination of partial kidney resection specimens", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "reference": {
            "PMID": "23139026", 
            "citation": "Liehr UB, Wendler JJ, Blaschke S, Porsch M, Janitzky A, Baumunk D, Pech M, Fischbach F, Schindele D, Grube C, Ricke J, Schostak M. [Irreversible electroporation: the new generation of local ablation techniques for renal cell carcinoma]. Urologe A. 2012 Dec;51(12):1728-34. doi: 10.1007/s00120-012-3038-8. German."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967407"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Magdeburg", 
            "investigator_full_name": "Johann Wendler", 
            "investigator_title": "Dr. med.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "adverse effects\nAssessment of the procedural compliance\nAssessment of the Quality of Life (QoL)", 
            "measure": "safety", 
            "safety_issue": "Yes", 
            "time_frame": "4 month"
        }, 
        "source": "University of Magdeburg", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Magdeburg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}